Levofloxacin for the treatment of pyelonephritis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1241-1253

  Rafat, Cédric ^a   Debrix, Isabelle ^a   Hertig, Alexandre ^a  

^a HÔPITAL TENON   (France)

Author keywords

Bacterial resistance; Fluoroquinolone; Levofloxacin; Pyelonephritis; Urinary tract infection

Indexed keywords

CEPHALOSPORIN; CIPROFLOXACIN; CXA 201; GEMIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PLAZOMICIN; SITAFLOXACIN; TAZOBACTAM; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CARDIOTOXICITY; CREATININE CLEARANCE; DIARRHEA; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGLYCEMIA; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; OUTPATIENT CARE; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTOXICITY; PRACTICE GUIDELINE; PRESCRIPTION; PYELONEPHRITIS; QT PROLONGATION; REVIEW; TENDINITIS; TENDON RUPTURE; TREATMENT DURATION; URINARY EXCRETION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; LEVOFLOXACIN; PRACTICE GUIDELINES AS TOPIC; PYELONEPHRITIS; URINARY TRACT INFECTIONS;

EID: 84877910093     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.792805     Document Type: Review

References (129)

1. Stamm WE, Hooton TM, Johnson JR, et al. Urinary tract infections: from pathogenesis to treatment. J Infect Dis 7. 1989;159(3):400-6
2. Czaja CA, Scholes D, Hooton TM, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007;45(3):273-80
3. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 2005;23(11):1123-42
4. Caterino JM, Weed SG, Espinola JA, et al. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005. Acad Emerg Med 2009;16(6):500-7
5. Bush LM, Chaparro-Rojas F, Okeh V, et al. Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy. Infect Drug Resist 2011;4:4177-89
6. Bouchillon S, Hoban DJ, Badal R, et al. Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010. Open Microbiol J 2012;6:674-8
7. Pitout JD, Nordmann P, Laupland KB, et al. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56(1):52-9
8. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5):e103-20
9. Une T, Fujimoto T, Sato K, et al. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988;32(9):1336-40
10. Inagaki Y, Horiuchi S, Une T, et al. In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea. J Antimicrob Chemother 1989;24(4):547-9
11. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279(2):125-9
12. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37(5):1073-81
13. Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents 2008;32(4):320-5
14. Miller LG, Mehrotra R, Tang AW. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? Int J Antimicrob Agents 2007;29(5):605-7
15. Nicolle L, Duckworth H, Sitar D, et al. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. Int J Antimicrob Agents 2008;31(3):287-9
16. Deguchi T, Nakane K, Yasuda M, et al. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents 2010;35(6):573-7
17. Chen YH, Ko WC, Hsueh PR. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone- resistant uropathogens. Eur J Clin Microbiol Infect Dis 2012;31(8):1699-704
18. Houston AK, Jones RN. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn Microbiol Infect Dis 1994;18(1):57-9
19. Licata L, Smith CE, Goldschmidt RM, et al. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41(5):950-5
20. Ozbek B, Otuk G. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa. Chemotherapy 2009;55(6):446-50
21. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32(2):101-19
22. Cohen KA, Lautenbach E, Weiner MG, et al. Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance. Infect Control Hosp Epidemiol 2008;29(10):975-7
23. Yen YH, Chen HY, Wuan-Jin L, et al. Clinical and economic impact of a pharmacist-managed i.v.-to-p.o. conversion service for levofloxacin in Taiwan. Int J Clin Pharmacol Ther 2012;50(2):136-41
24. Wagenlehner FM, Kinzig-Schippers M, Sorgel F, et al. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006;28(6):551-9
25. Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41(7):1562-5
26. Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003;45(4):295-301
27. Gupta K, Sahm DF, Mayfield D, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001;33(1):89-94
28. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents 2002;19(1):21-31
29. Lagace-Wiens PR, Simner PJ, Forward KR, et al. Analysis of 3789 in-and outpatient Escherichia coli isolates from across Canada-results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69(3):314-19
30. Hoban DJ, Nicolle LE, Hawser S, et al. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011;70(4):507-11
31. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003;22(6):551-6
32. Sader HS, Fritsche TR, Jones RN. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). Diagn Microbiol Infect Dis 2007;58(1):27-32
33. Lu PL, Liu YC, Toh HS, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012;40(Suppl):S37-43
34. Gordon KA, Sader HS, Jones RN. Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States. Diagn Microbiol Infect Dis 2003;47(1):377-83
35. Lewin CS, Morrissey I, Smith JT. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis. J Pharm Pharmacol 1991;43(7):492-4
36. Peng MY. Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect 1999;32(1):33-9
37. Klimberg IW, Cox CE II, Fowler CL, et al. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998;51(4):610-15
38. Richard GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52(1):51-5
39. Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53(9):3782-92
40. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007;23(11):2637-45
41. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008;71(1):17-22
42. Paterson JM, Mamdani MM, Manno M, et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 2012;184(14):1565-70
43. Wise R, Lister D, McNulty CA, et al. The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother 1986;18(Suppl D):71-81
44. Bergogne-Berezin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet 2002;41(10):741-50
45. Webberley JM, Andrews JM, Ashby JP, et al. Pharmacokinetics and tissue penetration of orally administered pefloxacin. Eur J Clin Microbiol 1987;Oct;6(5):521-4
46. Frydman AM, Le Roux Y, Lefebvre MA, et al. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother. 1986;17(Suppl B):65-79.
47. Onrust SV, Lamb HM, Balfour JA. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Drugs 1998;56(5):895-928
48. Yuk JH, Nightingale CH, Quintiliani R, et al. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1991;35(2):384-6
49. Wagenlehner FM, Wydra S, Onda H, et al. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003;47(12):3789-94
50. LeBel M, Vallee F, Bergeron MG. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother 1986;29(3):501-5
51. Drusano GL, Plaisance KI, Forrest A, et al. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986;30(3):440-3
52. Brunner M, Stabeta H, Moller JG, et al. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 2002;46(12):3724-30
53. Naber KG, Theuretzbacher U, Moneva-Koucheva G, et al. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1999;18(11):783-9
54. Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents 2008;32(4):320-5
55. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41(10):2256-60
56. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32(2):101-19
57. Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998;42(8):2060-5
58. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43 (Suppl B):83-90.
59. Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995;39(1):170-4
60. Gee T, Andrews JM, Ashby JP, et al. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J Antimicrob Chemother 2001;47(4):431-4
61. Allen A, Bygate E, Oliver S, et al. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob Agents Chemother 2000;44(6):1604-8
62. Landersdorfer CB, Kirkpatrick CM, Kinzig M, et al. Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. Antimicrob Agents Chemother 2009;53(9):3902-7
63. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31(Suppl 2S):24-8
64. Singh R, Swick MC, Ledesma KR, et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012;56(4):1680-5
65. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45(1):105-16
66. Matsumoto M, Shigemura K, Shirakawa T, et al. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography. Int J Antimicrob Agents 2012;40(5):440-4
67. Wang M, Sahm DF, Jacoby GA, et al. Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother 2004;48(4):1400-1
68. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006;6(10):629-40
69. Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? Clin Microbiol Infect 2008;14(4):295-7
70. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351(9105):797-9
71. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006;12(1):83-8
72. van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14(11):1722-30
73. Vellinga A, Murphy AW, Hanahoe B, et al. A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother 2010;65(7):1514-20
74. van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;66(3):650-6
75. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008;121(10):876-84
76. Smith SP, Manges AR, Riley LW. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition. Clin Infect Dis 2008;46(5):689-95
77. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012;2012:976273
78. Naber KG, Schito G, Botto H, et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54(5):1164-75
79. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003;51(1):69-76
80. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012;39(1):45-51
81. Talan DA, Krishnadasan A, Abrahamian FM, et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole-and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008;47(9):1150-8
82. Rattanaumpawan P, Tolomeo P, Bilker WB, et al. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect 2010;76(4):324-7
83. Khawcharoenporn T, Vasoo S, Ward E, et al. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012;30(1):68-74
84. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005;26(5):380-8
85. Neuzillet Y, Negrier S, Fizazi K, et al. The French clinical trials ongoing (GETUG and AFU) on urothelial carcinomas, kidney and prostate cancers. Prog Urol 2010;20(Suppl):1S84-9
86. Rock W, Colodner R, Chazan B, et al. Ten years surveillance of antimicrobial susceptibility of community-acquired Escherichia coli and other uropathogens in northern Israel (1995-2005). Isr Med Assoc J 2007;9(11):803-5
87. Sanchez GV, Master RN, Karlowsky JA, et al. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012;56(4):2181-3
88. Karlowsky JA, Lagace-Wiens PR, Simner PJ, et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother 2011;55(7):3169-75
89. Gales AC, Sader HS, Jones RN. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002;44(3):289-99
90. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37(12):1643-8
91. Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009;65(4):414-26
92. Pitout JD, Church DL, Gregson DB, et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the calgary health region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 2007;51(4):1281-6
93. Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004;54(4):735-43
94. Bartoloni A, Pallecchi L, Riccobono E, et al. Relentless increase of resistance to fluoroquinolones and expanded-spectrum cephalosporins in Escherichia coli: 20 years of surveillance in resource-limited settings from Latin America. Clin Microbiol Infect 2013;19(4):356-61
95. Simner PJ, Zhanel GG, Pitout J, et al. Prevalence and characterization of extended-spectrum beta-lactamase-and AmpC beta-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69(3):326-34
96. Xiong Z, Zhu D, Wang F, et al. Investigation of extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli from China. Diagn Microbiol Infect Dis 2002;44(2):195-200
97. Seo MR, Park YS, Pai H. Characteristics of plasmid-mediated quinolone resistance genes in extended-spectrum cephalosporin-resistant isolates of Klebsiella pneumoniae and Escherichia coli in Korea. Chemotherapy 2010;56(1):46-53
98. http://www.uroweb.org/gls/pdf/15-Urological-Infections.pdf
99. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001;47(Suppl):14-39.discussion 44-8
100. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5):466-72
101. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26(3):273-80
102. Deshpande A, Pant C, Jain A, et al. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 2008;24(2):329-33
103. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23(3):529-49
104. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007;45(6):695-703
105. Vardakas KZ, Konstantelias AA, Loizidis G, et al. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis 2012;16(11):e768-73
106. Williams D, Hopkins S. Safety of trovafloxacin in treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1998;17(6):454-8
107. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003;51(Suppl):121-7
108. Bellon A, Perez-Garcia G, Coverdale JH, et al. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol 2009;65(10):959-62
109. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33(4):685-706
110. Martin SJ, Meyer JM, Chuck SK, et al. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother 1998;32(3):320-36
111. Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001;35(12):1540-7
112. Tome AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 2011;34(6):465-88
113. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998;20(6):1049-70
114. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010;33(5):353-69
115. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011;120(2):103-10
116. Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59(1):122-6
117. Noel GJ, Goodman DB, Chien S, et al. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004;44(5):464-73
118. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21(12):1468-72
119. Gold L, Igra H. Levofloxacin-induced tendon rupture: a case report and review of the literature. J Am Board Fam Pract 2003;16(5):458-60
120. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010;27(3):193-209
121. van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324(7349):1306-7
122. Ge DT, Law PY, Kong SK, et al. Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett 2009;184(2):81-4
123. Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497(1):111-17
124. Aspinall SL, Good CB, Jiang R, et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009;49(3):402-8
125. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30(4):397-404
126. Figueira-Coelho J, Pereira O, Picado B, et al. Acute hepatitis associated with the use of levofloxacin. Clin Ther 2010;32(10):1733-7
127. Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009;34(5):407-13
128. Cao X, Cavaco LM, Lv Y, et al. Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals. J Clin Microbiol 2011;49(7):2496-501
129. Gales AC, Castanheira M, Jones RN, et al. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012;73(4):354-60